BIO
Bio-Rad Laboratories A·NYSE
--
--(--)
--
--(--)
9.05 / 10
Outperform
Financial evaluation shows BIO has exceptional fundamentals, scoring 9.1/10. Key strengths include high net profit margin (2.11%) and efficient current assets turnover (0.6437), placing it in top performance groups. However, Total operating revenue growth is negative (-0.4739 YoY), and Asset-MV is suboptimal (-0.5007), both in lower groups. These factors collectively suggest solid profitability but slowing top-line growth and potential valuation concerns, leading to an overall Outperform rating with caveats.
Analysis Checks(8/10)
Revenue-MV
Value-0.23
Score2/3
Weight25.27%
1M Return3.00%
Value-0.23
Score2/3
Weight25.27%
1M Return3.00%
Total operating revenue (YoY growth rate %)
Value-0.47
Score1/3
Weight-15.83%
1M Return-2.56%
Value-0.47
Score1/3
Weight-15.83%
1M Return-2.56%
Net income-Revenue
Value-0.17
Score3/3
Weight58.83%
1M Return5.60%
Value-0.17
Score3/3
Weight58.83%
1M Return5.60%
Current assets turnover ratio
Value0.64
Score2/3
Weight2.03%
1M Return0.26%
Value0.64
Score2/3
Weight2.03%
1M Return0.26%
Asset-MV
Value-0.50
Score0/3
Weight-15.18%
1M Return-6.43%
Value-0.50
Score0/3
Weight-15.18%
1M Return-6.43%
Net profit attributable to parent company shareholders / Net profit (%)
Value100.00
Score2/3
Weight-11.55%
1M Return-1.63%
Value100.00
Score2/3
Weight-11.55%
1M Return-1.63%
Net cash flow from operating activities / Operating revenue (%)
Value19.43
Score3/3
Weight13.79%
1M Return1.58%
Value19.43
Score3/3
Weight13.79%
1M Return1.58%
Net profit margin (%)
Value2.11
Score3/3
Weight13.21%
1M Return1.57%
Value2.11
Score3/3
Weight13.21%
1M Return1.57%
EBIT / Total operating revenue (%)
Value5.46
Score3/3
Weight16.22%
1M Return1.88%
Value5.46
Score3/3
Weight16.22%
1M Return1.88%
Net profit / Total operating revenue (%)
Value2.11
Score3/3
Weight13.21%
1M Return1.57%
Value2.11
Score3/3
Weight13.21%
1M Return1.57%
Revenue-MV
Value-0.23
Score2/3
Weight25.27%
1M Return3.00%
Value-0.23
Score2/3
Weight25.27%
1M Return3.00%
Net profit attributable to parent company shareholders / Net profit (%)
Value100.00
Score2/3
Weight-11.55%
1M Return-1.63%
Value100.00
Score2/3
Weight-11.55%
1M Return-1.63%
Total operating revenue (YoY growth rate %)
Value-0.47
Score1/3
Weight-15.83%
1M Return-2.56%
Value-0.47
Score1/3
Weight-15.83%
1M Return-2.56%
Net cash flow from operating activities / Operating revenue (%)
Value19.43
Score3/3
Weight13.79%
1M Return1.58%
Value19.43
Score3/3
Weight13.79%
1M Return1.58%
Net income-Revenue
Value-0.17
Score3/3
Weight58.83%
1M Return5.60%
Value-0.17
Score3/3
Weight58.83%
1M Return5.60%
Net profit margin (%)
Value2.11
Score3/3
Weight13.21%
1M Return1.57%
Value2.11
Score3/3
Weight13.21%
1M Return1.57%
Current assets turnover ratio
Value0.64
Score2/3
Weight2.03%
1M Return0.26%
Value0.64
Score2/3
Weight2.03%
1M Return0.26%
EBIT / Total operating revenue (%)
Value5.46
Score3/3
Weight16.22%
1M Return1.88%
Value5.46
Score3/3
Weight16.22%
1M Return1.88%
Asset-MV
Value-0.50
Score0/3
Weight-15.18%
1M Return-6.43%
Value-0.50
Score0/3
Weight-15.18%
1M Return-6.43%
Net profit / Total operating revenue (%)
Value2.11
Score3/3
Weight13.21%
1M Return1.57%
Value2.11
Score3/3
Weight13.21%
1M Return1.57%
Is BIO undervalued or overvalued?
- BIO scores 9.05/10 on fundamentals and holds a Discounted valuation at present. Backed by its 0.60% ROE, -26.43% net margin, -12.03 P/E ratio, 1.21 P/B ratio, and 14.49% earnings growth, these metrics solidify its Outperform investment rating.
